The state of Connecticut currently has 16 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Open Label, 6-month Study for High Frequency and Chronic Migraine,
NCT06133491
Recruiting
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published, legacy injection paradigm (referred to herein as the "standard paradigm"). The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/04/2024
Locations: New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Chronic Migraine, Headache
Register for Updates
An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention
NCT06154070
Recruiting
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs(monthly migraine days)/month) requiring preventive treatment. Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern). The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase as well as the Post Treatment (4 weeks). There are 2 sites in the U.S. participating, where... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/04/2024
Locations: New England Institute For Clinical Research, Stamford, Connecticut
Conditions: Migraine Disorders
Register for Updates
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601
Recruiting
A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.
Gender:
All
Ages:
Between 6 years and 11 years
Trial Updated:
02/14/2024
Locations: Upsher-Smith Clinical Trial Site #1, Stamford, Connecticut
Conditions: Migraine Disorders
Register for Updates
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320
Recruiting
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/07/2024
Locations: Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut
Conditions: Episodic Migraine
Register for Updates